Overcoming MCL-1-driven adaptive resistance to targeted therapies

Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...

Descripción completa

Detalles Bibliográficos
Autor principal: Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985132/
https://www.ncbi.nlm.nih.gov/pubmed/31988312
http://dx.doi.org/10.1038/s41467-020-14392-z
Descripción
Sumario:Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.

Ejemplares similares